ClinicalTrials.gg
Sign In
Active, not recruitingNCT07742657Updated Aug 3, 2026

A Clinical Trial to Evaluate the Effects of Super Liver Liquid Drops on Gut Health, Digestive Comfort, and Daily Energy Levels

An interventional study of Super Liver in Gastrointestinal Symptoms, Bloating and Digestive Discomfort, sponsored by SuperBonsai Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by SuperBonsai Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
All
01

Study summary

This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. All 35 enrolled participants will self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each) in the morning with breakfast for the full 12-week intervention period.

Participants will complete validated questionnaires and self-reported assessments at Baseline, Week 2, Week 4, Week 8, and Week 12 via the Citruslabs study platform. All study activities will be conducted remotely.

02

Conditions studied

  • Gastrointestinal Symptoms
  • Bloating
  • Digestive Discomfort
  • Low Energy Levels
  • Brain Fog
  • Mood Instability
  • Sleep Quality
  • Skin Clarity
  • Facial Puffiness
  • Bad Breath
03

In context

Mental Fatigue

175 studies on the registry are indexed under Mental Fatigue; 54 are open to participants now.

This study's enrollment of 35 is below the median of 45 across 143 interventional studies indexed under Mental Fatigue.

Browse Mental Fatigue studies →

Lead sponsor

SuperBonsai Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be male or female.
  • Be aged 30-65 years (inclusive) at the time of enrollment.
  • Over the past four weeks, has had concerns regarding low energy levels and at least two of the following: Bloating, Digestion, Irregular Bowel movements, Brain fog.
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Willing and able to follow the study protocol as described.
  • Willing to maintain their current diet, exercise routine, and sleep patterns, for the duration of the trial.
  • If taking other over-the-counter supplements or herbal remedies is willing to maintain this routine without introducing any other new products for the study duration.
  • Resides in the United States.
  • Willing to follow the study protocol as described.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or sensitivity to any of the study product ingredients (milk thistle, dandelion, yellow dock, turmeric, ginger, chicory/inulin, berberine).
  • Known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, or gastrointestinal tract surgeries.
  • Known history of gallbladder disease or bile duct obstruction.
  • Has a chronic health condition that could impact participation in this study, such as oncological or psychiatric disorders.
  • Has a planned surgery in the next 12 weeks.
  • Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Known history of substance abuse.
  • Currently, or was in the past 3 months, a smoker.
  • Currently participating in or planning to participate in another research study during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Super Liver Arm

    Dietary Supplement: Super Liver

Interventions

  • Dietary supplementSuper Liver

    All 35 enrolled participants self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each), taken in the morning with breakfast, for 12 consecutive weeks.

06

What researchers measure

Primary outcomes

  1. Change in Gastrointestinal Symptom Rating Scale (GSRS)

    Change from baseline to Week 12 in gastrointestinal symptom severity as assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Higher scores indicate greater gastrointestinal symptom severity.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Self-Reported Energy Level Score

    Change from baseline to Week 12 in participant-reported energy level, as assessed using the study questionnaire.

    Time frame: Baseline to Week 12

  2. Change in Self-Reported Brain Fog Score

    Change from baseline to Week 12 in participant-reported brain fog, as assessed using the study questionnaire.

    Time frame: Baseline to Week 12

  3. Change in Self-Reported Mood Stability Score

    Change from baseline to Week 12 in participant-reported mood stability, as assessed using the study questionnaire.

    Time frame: Baseline to Week 12

  4. Change in Self-Reported Sleep Quality Score

    Change from baseline to Week 12 in participant-reported sleep quality, as assessed using the study questionnaire.

    Time frame: Baseline to Week 12

  5. Change in Self-Reported Skin Clarity Score

    Change from baseline to Week 12 in participant-reported skin clarity, as assessed using the study questionnaire.

    Time frame: Baseline to Week 12

  6. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)

    Incidence, severity, and relationship to study product of treatment-emergent adverse events occurring from the first dose of study product through the end of the 12-week study period.

    Time frame: Continuous monitoring over 12 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2026, 3 months after the start.

Of 92 interventional studies with no phase under Mental Fatigue, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Aug 3, 2026
StartActual
Jun 24, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07742657
Lead sponsor
SuperBonsai Inc.
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Jun 24, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Mental Fatigue →

Other studies from this sponsor

SuperBonsai Inc.

Start the discussion